Alexander E Berezin1, Alexander A Kremzer2, Tatyana A Samura2, Tatyana A Berezina3. 1. Internal Medicine Department, State Medical University, Zaporozhye, 69035, Ukraine. 2. Clinical Pharmacology Department, State Medical University, Zaporozhye, 69035, Ukraine. 3. Private Medical Center 'Vita-Center', Zaporozhye, 69000, Ukraine.
Abstract
Aim: to evaluate the associations between signatures of apoptotic endothelial cell-derived microvesicles (MVs) with phenotypes of chronic heart failure (HF). Methods: The study cohort consisted of 388 prospectively involved subjects with HF patients with predominantly reduced left ventricular ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). All biomarkers were measured at baseline. Results: The number of circulating CD31+/annexin V+ MVs in HFrEF and HFmrEF patients was similar. The number of circulating CD144+/annexin V+ MVs in HFrEF patients was significantly higher than HFmrEF and HFpEF. We determined that a combination of number of circulating CD31+/annexin V+ MVs and Gal-3 was the best predictor of HFpEF and that number of circulating CD144+/annexin V+ MVs is able to increase predictive capabilities of soluble ST2 (sST2) and Gal-3 for HFrEF. Conclusion: We found that the number of circulating CD31+/annexin V+ MVs may improve a predictive capacity for conventional HF biomarkers.
Aim: to evaluate the associations between signatures of apoptotic endothelial cell-derived microvesicles (MVs) with phenotypes of chronic heart failure (HF). Methods: The study cohort consisted of 388 prospectively involved subjects with HF patients with predominantly reduced left ventricular ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). All biomarkers were measured at baseline. Results: The number of circulating CD31+/annexin V+ MVs in HFrEF and HFmrEF patients was similar. The number of circulating CD144+/annexin V+ MVs in HFrEF patients was significantly higher than HFmrEF and HFpEF. We determined that a combination of number of circulating CD31+/annexin V+ MVs and Gal-3 was the best predictor of HFpEF and that number of circulating CD144+/annexin V+ MVs is able to increase predictive capabilities of soluble ST2 (sST2) and Gal-3 for HFrEF. Conclusion: We found that the number of circulating CD31+/annexin V+ MVs may improve a predictive capacity for conventional HF biomarkers.
Authors: Houssam Aheget; María Tristán-Manzano; Loubna Mazini; Marina Cortijo-Gutierrez; Pablo Galindo-Moreno; Concha Herrera; Francisco Martin; Juan Antonio Marchal; Karim Benabdellah Journal: J Clin Med Date: 2020-07-26 Impact factor: 4.241
Authors: Michiel T H M Henkens; Sharon Remmelzwaal; Emma L Robinson; Adriana J van Ballegooijen; Arantxa Barandiarán Aizpurua; Job A J Verdonschot; Anne G Raafs; Jerremy Weerts; Mark R Hazebroek; Sandra Sanders-van Wijk; M Louis Handoko; Hester M den Ruijter; Carolyn S P Lam; Rudolf A de Boer; Walter J Paulus; Vanessa P M van Empel; Rein Vos; Hans-Peter Brunner-La Rocca; Joline W J Beulens; Stephane R B Heymans Journal: Eur J Heart Fail Date: 2020-08-07 Impact factor: 15.534